Biocon Limited

Report DateResearch houseDescriptionRecoAt PriceTarget PriceUpSide
/DownSide
Download
22-Oct-18 Motilal Oswal Positive Committee opinion Neutral 658 625 -5.02
24-Sep-18 Motilal Oswal Favorable regulatory outcome enhances biosimilars prospects Buy 665 625 -6.02
11-Apr-18 SPA Securities Front runner in Biosimilars to guide revenues going ahead 612
3-Dec-17 Motilal Oswal Mylan/ Biocon received Trastuzumab approval in US Neutral 447 485 8.5
27-Oct-17 Nirmal Bang Sec Slowdown In Biosimilar Business As Well As Licensing Income Sell 360 308 -14.44

Upcoming Events and Recent Updates

22-Aug-19
Post ITs (Interesting Article) - Biocon''s Malaysian arm gets EU GMP certification for insulin manufacturing facility  ( updated on Aug 23 2019)
Download 22-Aug-19
Management Interview - Kiran Mazumdar Shaw,CMD - kiranshaw CMD, Biocon limited says biologics business is at an inflection point  ( updated on Aug 22 2019)
22-Aug-19
Press Release  ( updated on Aug 22 2019)
21-Aug-19
Post ITs (Interesting Article) - Temasek, TrueNorth-CPPIB seek to invest in Biocon Biologics  ( updated on Aug 22 2019)

Analyst Calls / Meets


Management Interviews

22-Aug-19 Kiran Mazumdar ..  
30-Jul-19 Kiran Mazumdar ..  
26-Jul-19 Kiran Mazumdar ..  
08-Jul-19 Kiran Mazumdar ..  
15-May-19 Kiran Mazumdar ..  

Investor Presentations


Annual Reports
Source: Reportjunction.com

2018-19  
2017-18  
2016-17  
2015-16  
2014-15  

Research Showcase

22-Oct-18
Motilal Oswal -..
Download
24-Sep-18
Motilal Oswal -..
Download
11-Apr-18
SPA Securities ..
Download
03-Dec-17
Motilal Oswal -..
Download
27-Oct-17
Nirmal Bang Sec..
Download

Results

26-Jul-19 Results
26-Apr-19 Results
25-Apr-19 Results
24-Jan-19 Results
25-Oct-18 Results

AGM/EGM/Board Meetings

26-Jul-19 - AGM
25-Jul-19 - Quarterly Results
04-Jun-19 - POM
24-Jan-19 - Quarterly Results
27-Jul-18 - AGM

Press Release

22-Aug-19 Press Release
01-Aug-19 Press Release
25-Jul-19 Press Release
25-Apr-19 Press Release
24-Jan-19 Press Release

 

Archived Documents

No Archieved Transcript.